Physician profile
Alex Gibberman
NPI 1659785178
$6,348.48
in general payments reported to CMS, 2019-2025
21 companies · $578 in 2025
The $578 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $412 · 2021: $708 · 2022: $576 · 2023: $2,631 · 2024: $535 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,678 · Gift: $51.85 · Education: $14.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,677.82 |
| Gift | $51.85 |
| Education | $14.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $2,303.78 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $664.67 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $615.04 | 2022-2025 | Alden Scleral Zenlens, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $573.36 | 2019-2025 | Acuvue |
| Allergan, INC. | $444.07 | 2019-2022 | |
| Coopervision INC. | $260.06 | 2019-2024 | Myday Contact Lens |
| Alcon Vision LLC | $240.47 | 2019-2025 | Tryptyr |
| Novartis Pharmaceuticals Corporation | $240.10 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $183.14 | 2019-2023 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $182.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $126.97 | 2022 | |
| Apellis Pharmaceuticals, INC. | $120.63 | 2024 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $116.57 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $64.73 | 2021 | |
| Shire North American Group INC | $47.23 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $39.75 | 2025 | Photrexa Viscous and Photrexa |
| Lombart Brothers, INC. | $30.32 | 2020 | |
| Dompe US, INC. | $27.14 | 2024 | Oxervate |
| Eyevance Pharmaceuticals LLC | $24.77 | 2020 | |
| Kala Pharmaceuticals, INC. | $21.80 | 2022 | |
| Abbvie INC. | $21.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Gibberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.